News

Published on 15 Nov 2022 on Zacks via Yahoo Finance

How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246%


Article preview image

Annexon, Inc. (ANNX) closed the last trading session at $6.01, gaining 6.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $20.80 indicates a 246.1% upside potential.

The average comprises five short-term price targets ranging from a low of $7 to a high of $30, with a standard deviation of $8.47. While the lowest estimate indicates an increase of 16.5% from the current price level, the most optimistic estimate points to a 399.2% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.

NASDAQ.ANNX price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Are Medical Stocks Lagging Annexon (ANNX) This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the gro...

Zacks via Yahoo Finance 18 Apr 2024

Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know

Annexon, Inc. (ANNX) ended the recent trading session at $6.17, demonstrating a -0.96% swing from...

Zacks via Yahoo Finance 10 Apr 2024

Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade

Shares of Annexon, Inc. (ANNX) have gained 20.1% over the past four weeks to close the last tradi...

Zacks via Yahoo Finance 1 Apr 2024

What Makes Annexon (ANNX) a New Buy Stock

Investors might want to bet on Annexon, Inc. (ANNX), as it has been recently upgraded to a Zacks ...

Zacks via Yahoo Finance 1 Apr 2024

Steven Cohen's Point72 Asset Management Acquires New Stake in Annexon Inc

Overview of Steven Cohen (Trades, Portfolio)'s Investment in Annexon Inc Warning! GuruFocus has d...

GuruFocus.com via Yahoo Finance 13 Feb 2024

Recent uptick might appease Annexon, Inc. (NASDAQ:ANNX) institutional owners after losing 18% over...

Key Insights Given the large stake in the stock by institutions, Annexon's stock price might be v...

Simply Wall St. via Yahoo Finance 10 Feb 2024

Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the gro...

Zacks via Yahoo Finance 17 Jan 2024

Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How

Annexon, Inc. ANNX, a clinical-stage company, is focused on developing novel therapies to treat p...

Zacks via Yahoo Finance 14 Jan 2024

Muneer Satter Bought 5.9% More Shares In Annexon

Those following along with Annexon, Inc. (NASDAQ:ANNX) will no doubt be intrigued by the recent p...

Simply Wall St. via Yahoo Finance 31 Dec 2023

Annexon: ANX007 Advances Forward With Stellar Endpoint (NASDAQ:ANNX)

Annexon, Inc. has a promising complement inhibitor ANX007 treatment of patients with Geographic...

Seeking Alpha 23 Dec 2023